Identifying the Role of SF3B1 in the Metabolic Reprograming of Myelodysplastic Syndrome Stem Cells
2024
Overview
The Vera and Joseph Dresner Foundation granted the Regents of the University of Colorado a $250,000 grant over two years for early career investigator Dr. Maria L. Amaya.
Details
Dr. Amaya with the support of her mentor, Dr. Craig Jordan, will develop effective and well-tolerated treatments for SF3B1-mutant myelodysplastic syndromes (MDS). Dr. Amaya hypothesizes that SF3B1-mutant MDS cells have unique metabolic needs that can be targeted, leading to new treatment strategies for this population.
Learn more about Regents of the University of Colorado.